Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Controlled, Open-label Phase 2 Clinical Trial of HS-IT101 Injection Versus Chemotherapy for Patients With Advanced Melanoma

NCT07406724 is registered in ClinicalTrials.gov with Qingdao Sino-Cell Biomedicine Co., Ltd. as lead sponsor.

NCT NCT07406724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07406724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Controlled, Open-label Phase 2 Clinical Trial of HS-IT101 Injection Versus Chemotherapy for Patients With Advanced Melanoma
Lead sponsor
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 26, 2026
Completion date
December 31, 2028
Enrollment
90 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (excluding uveal melanoma)